EUCTR2017-001446-10-FR进行中（未招募）1 期
A - IFM2016-03
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 35
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864CTIS2023-506541-39-00Amgen Inc.377
进行中（未招募）
1 期
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)CTIS2023-506975-83-00Aprogen Inc.720
招募中
1 期
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic DermatitisAtopic DermatitisCTIS2022-502997-18-00Bristol-Myers Squibb Services Unlimited Company64
进行中（未招募）
1 期
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)Metastatic cancer, Epithelial tumoursCTIS2023-503525-19-00Akamis Bio Limited220
进行中（未招募）
1 期
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001Chronic Hepatitis BCTIS2023-504288-18-00Zhejiang Yaoyuan Biotechnology Co. Ltd.119